[Brazilian policy for the distribution and production of antiretroviral drugs: a privilege or a right?].
This article focuses on the Brazilian National AIDS Program and its policy of distributing and producing antiretroviral drugs, emphasizing links between local decisions and global HIV/AIDS policies. Emphasizing recent developments in the Brazilian and international scenario with regard to access to treatment for people with HIV/AIDS, the article highlights the participation by the pharmaceutical industry, governments, civil society, and UN agencies in establishing responses to the pandemic. The author concludes by identifying transnational activism as a key response to both the power of pharmaceutical corporations and the law of the market (including patent laws), thus fostering global solidarity for people with HIV/AIDS.
Galvao
Jane
J
School of Public Health, University of California, Berkeley, CA, 94720-7360, USA. jgalvao@uclink.berkeley.edu
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000600:supply & distribution*; D004345:Drug Industry; D006291:Health Policy / Q000331:legislation & jurisprudence; D006297:Health Services Accessibility / Q000331:legislation & jurisprudence; D006801:Humans; D007880:Legislation, Drug; D010330:Patents as Topic / Q000331:legislation & jurisprudence
D019380:Anti-HIV Agents